Finally, Rinatabart sesutecan (Rina-S, PRO1184), an ADC loaded with the topoisomerase 1 inhibitor exatecan, is currently under evaluation in ovarian cancer with varying levels of FRα expression [109]. Here, FOLR1 is linked to ovarian carcinoma.